StockData
Cullinan Therapeutics, Inc. logo

Cullinan Therapeutics, Inc. (CGEM) stock

CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$8.89−0.18 (-1.98%)

Close on Nov 20, 2026Market cap $572.11MP/E –Yield –

Cullinan Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Cullinan Therapeutics's free cash flow for the twelve months ending Dec 31, 2025 was -$175.80M. For fiscal 2025 it was -$175.80M. The highest annual figure on record is -$29.78M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$175.80M–
FY2024Dec 31, 2024-$145.30M–
FY2023Dec 31, 2023-$134.48M–
FY2022Dec 31, 2022-$127.80M–
FY2021Dec 31, 2021-$43.43M–
FY2020Dec 31, 2020-$29.78M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$38.12M–
Q4 FY2024Dec 31, 2024-$36.63M–
Q3 FY2024Sep 30, 2024-$34.14M–
Q2 FY2024Jun 30, 2024-$36.29M–
Q1 FY2024Mar 31, 2024-$38.25M–
Q4 FY2023Dec 31, 2023-$18.13M–
Q3 FY2023Sep 30, 2023-$34.14M–
Q2 FY2023Jun 30, 2023-$31.06M–
Q1 FY2023Mar 31, 2023-$51.16M–
Q4 FY2022Dec 31, 2022-$25.87M–
Q3 FY2022Sep 30, 2022-$54.60M–
Q2 FY2022Jun 30, 2022-$25.42M–
Q1 FY2022Mar 31, 2022-$21.91M–
Q4 FY2021Dec 31, 2021-$15.17M–
Q4 FY2020Dec 31, 2020-$9.44M–
Q3 FY2020Sep 30, 2020-$9.08M–
Q2 FY2020Jun 30, 2020-$6.25M–
Q1 FY2020Mar 31, 2020-$5.02M–

More Cullinan Therapeutics figures

See a number that looks wrong?